Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

Design and rationale of the YOSEMITE and RHINE trials: two phase 3 studies of faricimab in patients with diabetic macular edema

Nicole Eter; Jeffrey R Willis; Carlos Quezada Ruiz; Francis Abreu; Hugh Lin; David Silverman; Jane Ives; Karen Basu; Zdenka Haskova; Kemal Asik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1043. doi:

ARVO Annual Meeting Abstract June 2021

Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials

John A Wells; Charles Clifton Wykoff; Jeffrey R Willis; Zdenka Haskova; Hugh Lin; David Silverman; Anthony P Adamis; Jane Ives; Francis Abreu; Karen Basu; Ramin Tadayoni

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1037. doi:

ARVO Annual Meeting Abstract June 2021

Dual angiopoietin-2 and VEGF-A inhibition with faricimab in neovascular age-related macular degeneration: phase 3 TENAYA and LUCERNE trial design

Robyn H Guymer; Carlos Quezada Ruiz; Jeffrey R Willis; David Silverman; Jane Ives; Karen Basu; Balakumar Swaminathan; Aachal Kotecha; Heather Boston; Hugh Lin

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):429. doi:

ARVO Annual Meeting Abstract June 2021

Faricimab in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials

Arshad M. Khanani; Jeffrey Heier; Carlos Quezada Ruiz; Hugh Lin; David Silverman; Christopher Brittain; Jane Ives; Balakumar Swaminathan; Karen Basu; Tien Y Wong

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):428. doi:

Advertisement